Regenxbio RGNX
NASDAQ RGNX
$8.94 -0.26 (-2.83%)
As of: Sep 4, 2026 · 3:59 PM EDT

Regenxbio (RGNX) EBT Margin Growth (3y) (2017 - 2026)

Analysis

Regenxbio (RGNX) EBT Margin Growth (3y) (2017 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -484.00
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 132.00
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 6,691.00
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -2,054.00
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 8,006.00
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 9,980.00
8 Royalty Pharma 28.45 Bn 27.61 Bn - -5,319.00
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 31,363.00
10 Regenxbio 472.74 Mn 367.22 Mn - 38,173.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 38,173.00
Dec 31, 2025 -3,006.00
Sep 30, 2025 7,633.00
Jun 30, 2025 -12,308.00
Mar 31, 2025 35,231.00
Dec 31, 2024 -31,881.00
Sep 30, 2024 -5,661.00
Jun 30, 2024 2,378.00
Mar 31, 2024 -14,014.00
Dec 31, 2023 -9,496.00
Sep 30, 2023 -22,286.00
Jun 30, 2023 -15,390.00
Mar 31, 2023 -12,147.00
Dec 31, 2022 5,385.00
Sep 30, 2022 -4,833.00
Jun 30, 2022 -18,870.00
Mar 31, 2022 330,812.00
Dec 31, 2021 6,244.00
Sep 30, 2021 19,645.00
Jun 30, 2021 -29,766.00